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Abstract
Background: Protease activated receptor-2 (PAR-2) has been implicated in cellular proliferation,
invasion and metastasis in various tumors. Lymph node metastasis is an important patient
prognostic factor for uterine cervical cancers. This prompted us to study the role of PAR-2 in
lymph node metastasis of uterine cervical cancers.
Methods: Thirty patients underwent surgery for uterine cervical cancers. PAR-2 histoscores and
mRNA levels were determined by immunohistochemistry and real-time reverse transcription-
polymerase chain reaction, respectively. Patient prognosis was analyzed with a 48-month survival
rate.
Results:  PAR-2 histoscores and mRNA levels significantly (P  < 0.05) increased in 12 of 30
metastatic lymph node lesions from the corresponding primary tumor. The 48-month survival rate
of the 12 patients with increased PAR-2 levels in metastatic lymph nodes was 42%, while the rate
of the other 18 patients with no change in PAR-2 levels was 82%, regardless of histopathological
type.
Conclusion: PAR-2 might work on lymph node metastasis of uterine cervical cancers, and is
considered to be a novel prognostic indicator for uterine cervical cancers.
Background
The conventional role of serine proteases in tumor biol-
ogy has changed with the recent discovery of a family of
protease activated receptors (PARs). Beside contribution
to cancer progression, by the degradation of extracellular
matrix protein, it is now clear that some proteases serve as
signal molecules controlling cell functions through this
new class of receptors; which belongs to the superfamily
of the serpentine G protein-coupled receptors. These
receptors are activated by serine proteases that cleave
within the extracellular amino terminus to expose a teth-
ered ligand domain [1]. The new ligand binds to the core
of the receptor and initiates signal transduction that
results in mitogen-activating protein kinase activation [2-
4], cytosolic calcium mobilization [5,6], and cell prolifer-
ation [7,8]. Macromolecular assembly and generation of
serine proteases on cellular surfaces are largely involved in
the regulation of the metastatic cascade [9]. Most impor-
tantly, it may provide a framework to define the role of
distinct PARs in angiogenesis and tumor metastasis. The
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second member of the PAR family, PAR-2, is activated
mainly by trypsin-like proteases [1]. The gene encoding
human PAR-2 was isolated from a human genomic cDNA
library using hybridization to a probe derived from the 3'
exon of the mouse PAR-2 gene [10] and subsequently
cloned from human kidney cDNA [10,11] localized to
chromosome 5q13 [12].
PAR-2 is widely expressed in the gastrointestinal tract,
pancreas, kidney, liver, lung, vasculature, eye, prostate,
ovary and uterus [11,13]. PAR-2 expression has also been
observed in cancers of the lungs [14], liver [15], prostate
[11,16], thyroid [15], breast [15,17], gastrium [18-20],
colon [21,7], pancreas [22,23], gallbladder [24], and
melanoma [16] and glioblastoma [25]. PAR-2 mRNA
expression in lung cancers, increased by 16 fold in pulmo-
nary tumor alveolar walls, compared to normal alveolar
tissues [14]. In breast cancers, there is an upregulation of
PAR-2 in proliferating stromal fibroblasts surrounding the
carcinoma cells [15]. In gastric cancer cells, MKN-1,
trypsin stimulates an integrin α5β1-dependent adhesion
to fibronectin and proliferation through PAR-2 [20]. PAR-
2 promotes tumor cell proliferation of the colon [7,21],
gastrium [19,20], pancreas [22,23], and glioblastoma
[25]. PAR-2 has been implicated in invasion and metasta-
sis in cancers of the breast [15,17], colon [7,21], gastrium
[19,20], pancreas [22,23], lungs [14], prostate [16], and
melanoma [16], and glioblastoma [25].
The presence of lymph node metastasis, recognized as the
most common metastatic lesion, is critical to patient prog-
nosis in uterine cervical cancers [26-29]. Elucidation of
the role of PAR-2, the manner of its expression in primary
tumor and the corresponding metastatic lymph node
lesions of uterine cervical cancers were studied.
Methods
Patients and tissues
Prior informed consent for the following studies was
obtained from all patients and approval was given by the
Research Committee for Human Subjects, Gifu University
School of Medicine. Thirty patients ranging from 28 to 74
years of age underwent surgery for cervical cancer stage IIb
(21 cases of squamous cell carcinoma, 5 cases of adeno-
carcinoma, and 4 cases of adenosquamouscarcinoma) at
the Department of Obstetrics and Gynecology, Gifu Uni-
versity School of Medicine, between January 2000 and
April 2004. Patient prognosis was analyzed in relation to
48-month survival rate. None of the patients had received
any pre-operative therapy. All cases involved direct exten-
sion to the parametrium histopathologically, and had
lymph node metastasis. Perfect lymphadenectomy was
performed and all lymph nodes taken were divided into
two. After surgery, the conventional radiotherapy for
lymph node metastasis was given as adjuvant therapy. The
chemotherapy with Mitomycin C, Vincristin and Cispla-
tin was performed when recurrence. The tissues of cervical
cancer were obtained immediately after surgery. The tis-
sues for RNA isolation were snap-frozen and stored at -
80°C, and those for immunohistochemistry were fixed
with 10% formalin and embedded in paraffin wax. The
clinical staging of cervical cancers was determined by
International Federation of Gynecology and Obstetrics
(FIGO) classification [30].
Immunohistochemistry
Four-μm sections of formalin-fixed paraffin-embedded
tissue samples from cervical cancers were cut with a micro-
tome and dried overnight at 37°C on a silanized-slide
(Dako, Carpinteria, CA, USA). The protocol of universal
Dako Labelled Streptavidin-Biotin kit (Dako, Carpinteria,
CA, USA) was followed for each sample. Samples were
deparaffinized in xylene at room temperature for 30 min-
utes, rehydrated with graded ethanol and washed in phos-
phate buffer saline (PBS). The samples were then placed
in 10 mM citrate buffer (pH 6.0) and boiled in a micro-
wave for 10 minutes for epitope retrieval. Endogenous
peroxidase activity was quenched by incubating tissue sec-
tions in 3% H2O2 for 10 minutes. The primary antibody,
goat PAR-2 (C-17, Santa Cruz Biotechnology, Santa Cruz,
CA, USA) was used overnight at 4°C at a dilution of
1:100. The slides were washed and biotinylated anti-goat
secondary antibody (Dako, Carpinteria, CA, USA) was
applied for 30 minutes. After rinsing in PBS, streptavidin-
conjugated horseradish peroxidase (Dako, Carpinteria,
CA, USA) was added for 30 minutes. Slides were then
washed and treated with the chromogen 3, 3'- diami-
nobenzidine (Dako, Carpinteria, CA, USA) for 5 minutes,
then rinsed in PBS, and counterstained with Mayer's
hematoxylin, dehydrated in graded ethanols, cleared in
xylene and cover-slipped with a mounting medium,
Entellan New (Merck, Darmstadt, Germany).
For the negative control of PAR-2 goat pre-immune ani-
mal serum (Dako, Carpinteria, CA, USA) was used instead
of the primary antibody.
Assessment of histochemical score (histoscore)
All sections of immunohistochemical staining for PAR-2
were evaluated in a semiquantitative fashion by two
pathologists according to the method described by McCa-
rty et al. [31], which considers both the intensity and the
percentage of cells stained at each intensity. Intensities
were classified as 0 (no staining), 1 (weak staining), 2
(distinct staining), 3 (strong staining) and 4 (very strong
staining). For each stained section, a value designated his-
toscore was obtained by application of the following algo-
rithm: histoscore = ∑(i+1) × Pi, where i and Pi represent
intensity and percentage of cells that stain at each inten-BMC Cancer 2008, 8:301 http://www.biomedcentral.com/1471-2407/8/301
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sity, respectively, and corresponding histoscores were cal-
culated separately.
Preparation of standard template for real-time 
polymerase chain reaction (PCR)
Internal standard template for real-time PCR was pro-
duced by PCR amplification using the primers of PAR-2
gene, 511–947 in the cDNA (PAR-2-TS: 5'-CTCCTCTCT-
GTCATCTGGTT-3' and PAR-2-TAS: 5'-CTGATCATCAG-
CACATAGGC-3'). The DNA template was purified using a
GeneClean II kit (Qbiogene, Irvine, CA, USA). The copy
numbers of the standard template were determined to
quantitate PAR-2 mRNA level in samples for real-time
reverse transcription (RT)-PCR.
Real-time RT-PCR
Total RNA was extracted with the acid guanidinium thio-
cyanate-phenol-chloroform method [32]. The total RNA
(3  μg) was reverse transcribed using Moloney murine
leukemia virus reverse transcriptase (MMLV-RT, 200 U/μl,
Invitrogen, Carlsbad, CA, USA) and the following rea-
gents: 250 mM Tris-HCl, pH 8.3, 375 mM KCl, 15 mM
MgCl2, 0.1 M dithiothreitol, 10 mM deoxynucleotide
[deoxyadenosine, deoxythymidine, deoxyguanosine and
deoxycystidine] tri-phosphates (dNTPs) mixture and ran-
dom hexamers (Invitrogen) at 37°C for 1 hour. The reac-
tion mixture was heated for 5 min at 94°C to inactivate
MMLV-RTase.
Real-time PCR reaction was performed with a Takara Ex
Taq R-PCR kit, version 1.0 (Takara, Otsu, Japan), using a
smart cycler system (Cepheid, Sunnyvale, CA, USA). The
reaction solution (25 μl) contained Takara Ex Taq HS (5
units/μl), 10×R-PCR Buffer, 250 mM Mg++ solution, 10
mM dNTP mixture, Sybr green I (1:1000 dilution; Cam-
brex, Otsu, Japan) and 20 μM of the primers of PAR-2
gene, 622–806 in the cDNA (PAR-2-S: 5'-AGAGGTATT-
GGGTCATCGTG-3' and PAR-2-AS: 5'-GCAGGAATGAA-
GATGGTCTG-3') with the transcribed total RNA from the
tissue and a serially diluted standard template. The real-
time PCR reactions were initially denatured by heating at
95°C for 30 seconds, followed by 40 cycles consisting of
denaturation at 94°C for 10 seconds, annealing at 55°C
for 5 seconds and extension at 72°C for 20 seconds. A
strong linear relationship between the threshold cycle and
the log concentration of the starting DNA copy number
was always shown (correlation coefficient > 0.99). Quan-
titative analysis was performed to determine the copy
number of each sample.
Statistical analysis
PAR-2 mRNA levels were determined from three parts
taken from each tumor, and each sample was analyzed in
triplicate. PAR-2 histoscores and mRNA levels were calcu-
lated using Student's t test. The 48-month survival rate
was calculated according to the Kaplan-Meier method,
and analyzed by the log-rank test. Differences were con-
sidered significant when P was less than 0.05.
Results
Immunohistochemical staining for PAR-2 on a represent-
ative case of non-keratinizing squamous cell carcinoma of
the cervix, both the primary tumor and metastatic lymph
node lesion are shown in Fig 1. PAR-2 was distributed in
the cancer cells in all cases studied.
There was no significant difference in PAR-2 expression
levels of the primary tumor of the cervix according to any
clinical backgrounds: age, clinical and surgical staging,
histopathology, lymph node metastasis including the
number of metastatic sites and adjuvant therapy (data not
shown).
The cases with increased PAR-2 histoscores from primary
tumor to the corresponding metastatic lymph node lesion
were the same as those with increased PAR-2 mRNA lev-
els. PAR-2 histoscores and mRNA levels in 12 of 30 meta-
static lymph node lesions of uterine cervical cancers were
significantly (P < 0.05 and P < 0.05, respectively) higher
than in the corresponding primary tumors, while the
scores and mRNA levels in the other 18 lesions were not
significantly altered (Fig 2). There was no significant dif-
ference in PAR-2 histoscores and mRNA levels according
to histopathological type (Fig 3).
Patient prognosis was correlated with a 48-month survival
rate. The prognosis of 12 patients with increased PAR-2
level in metastatic lesions was significantly poor (42%),
while that of the other 18 patients, with unchanged PAR-
2 level in metastatic lesions, was 82%. There was a signif-
icant (P < 0.01) difference in the 48-month survival rates
between the two groups (Fig 4).
There was no significant difference concerning clinical
variables such as age, histology, the number of metastatic
sites, and additional therapy after surgery, except for the
patient prognosis between cases of the increased PAR-2
and the unchanged PAR-2 (data not shown).
Discussion
The present data revealed that PAR-2 significantly
increased in metastatic lymph node lesions in comparison
with corresponding primary tumor and correlated with
poor patient prognosis in 12 out of 30 uterine cervical
cancers, regardless of histopathological types. Therefore,
PAR-2 might work on lymphogenous metastasis in uter-
ine cervical cancer, and be recognized as a novel prognos-
tic indicator for uterine cervical cancer. A plausible
hypothesis might be that a cancer cell enriched PAR-2 may
selectively work on lymphogenous metastasis and the BMC Cancer 2008, 8:301 http://www.biomedcentral.com/1471-2407/8/301
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Immunohistochemical staining for PAR-2 in primary tumor and the corresponding metastatic lymph node of uterine cervical  cancers (Original magnification, ×400) Figure 1
Immunohistochemical staining for PAR-2 in primary tumor and the corresponding metastatic lymph node of uterine cervical cancers 
(Original magnification, ×400). A representative case of squamous cell carcinoma of the uterine cervix, metastatic lesion in cardinal lymph nodes. 
Goat anti-human PAR-2 antibody (Santa Cruz) was used at a dilution of 1: 100 as the primary antibody. Dark brown staining represents positive for PAR-
2 antigen.
Primary tumor Metastatic lymph node
Negative control for primary tumor Negative control for metastatic lymph node Negative control for primary tumor Negative control for metastatic lymph node
PAR-2 histoscores and mRNA levels in primary tumor and the corresponding metastatic lymph node of uterine cervical can- cers Figure 2
PAR-2 histoscores and mRNA levels in primary tumor and the corresponding metastatic lymph node of uterine cervical cancers. In the 
primary tumor, alive and deceased cases are numbered in open and closed circles, respectively. In the metastatic lymph node, alive and deceased cases are 
numbered in open and closed boxes, respectively. Each level is the mean ± SD of 9 determinations. *, P < 0.05 versus each primary tumor.
P
A
R
-
2
 
m
R
N
A
 
(
1
0
5
D
N
A
 
c
o
p
y
/
μ
g
 
t
o
t
a
l
 
R
N
A
) 4
3
2
1
0
Primary
tumor
Metastatic
lymph node
4
7
10
11
13
14 17
29
1
2
3
5
6
8
9 12
15
16
18
19
20
21
22 23
24 25
26 27
28
30
4
7
10
11
13
14
17
29
1
2
3
5
6
8
9
12
15
16
18
19
20
21
22
23
24
25 26
27
28
30
*
*
*
*
* * *
* *
* *
*
P
A
R
-
2
h
i
s
t
o
s
c
o
r
e
Primary 
tumor
Metastatic
lymph node
400
300
200
100
0
3 14
4
7 10
11
13
29
2
5
6
8 9
12
15
16 18
19
20
21
22
23 24
25
26
27
28
30
1
17
4
7
10
11
13
14
17
29
1
2
3
5
6
8
9
12
15
16
18
19
20
2122
23
24
25
26
27
28
30
*
* *
* * *
*
*
*
**
*BMC Cancer 2008, 8:301 http://www.biomedcentral.com/1471-2407/8/301
Page 5 of 7
(page number not for citation purposes)
expression of PAR-2 would be increased from primary
tumor to the corresponding metastatic lymph node
lesion. Furthermore, such a phenomenon might induce a
cascade, causing PAR-2 expression to be increased in sec-
ondary metastatic lymph node lesions; resulting in poor
clinical prognosis. On the other hand, in cases with no
change in the PAR-2 level, PAR-2 might not directly con-
tribute to lymph node metastasis. Although lymph node
metastasis appears to be regulated by additional factors
besides PAR-2, such a cascade of lymph node metastasis
might be less active in these cases; resulting in compara-
tively better patient prognosis. This is novel evidence that
PAR-2 might contribute to aggressive lymphangitic metas-
tasis and that increase in PAR-2 from primary tumor to
metastatic lymph nodes might be a prognostic indicator.
Conclusion
PAR-2 might play an essential role as a signal to evoke and
maintain the cascade of lymph node metastasis. It is fur-
ther implicated for study to use PAR-2 as a tumor marker
for better patient prognosis.
PAR-2 histoscores and mRNA levels in primary tumor and the corresponding metastatic lymph node of uterine cervical can- cers classified according to histopathological types Figure 3
PAR-2 histoscores and mRNA levels in primary tumor and the corresponding metastatic lymph node of uter-
ine cervical cancers classified according to histopathological types. SCC, squamous cell carcinoma; ASC, adenosqua-
mous cell carcinoma; AD, adenocarcinoma. In the primary tumor, alive and deceased cases are numbered in open and closed 
circles, respectively. In the metastatic lymph node, alive and deceased cases are numbered in open and closed boxes, respec-
tively. Each level is the mean ± SD of 9 determinations.
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